GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease

• Published in: Cancer letters Vol. 376; no. 1; pp. 104 - 109
• Main Authors: Liu, Jingjing, Prager – van der Smissen, Wendy J.C, Look, Maxime P, Sieuwerts, Anieta M, Smid, Marcel, Meijer – van Gelder, Marion E, Foekens, John A, Hollestelle, Antoinette, Martens, John W.M
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 28.06.2016; Elsevier Limited
• Subjects: Antineoplastic Agents, Hormonal - adverse effects; Antineoplastic Agents, Hormonal - therapeutic use; Biomarkers, Tumor - genetics; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Cancer therapies; Chemotherapy; Chi-Square Distribution; Disease-Free Survival; DNA Mutational Analysis; Expression; Female; GATA3; GATA3 Transcription Factor - genetics; Gene expression; Gene Expression Regulation, Neoplastic; Hematology, Oncology and Palliative Medicine; Humans; Kaplan-Meier Estimate; Logistic Models; Medical prognosis; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Odds Ratio; Proportional Hazards Models; Protein expression; Proteins; Receptors, Estrogen - antagonists & inhibitors; Receptors, Estrogen - metabolism; Recurrent breast cancer; Retrospective Studies; Risk Factors; RNA, Messenger - genetics; Rodents; Selective Estrogen Receptor Modulators - adverse effects; Selective Estrogen Receptor Modulators - therapeutic use; Tamoxifen; Tamoxifen - adverse effects; Tamoxifen - therapeutic use; Time Factors; Treatment Outcome; PR; reverse transcriptase quantitative PCR; GATA-binding protein 3; recurrent breast cancer; HR; GATA3; odds ratio; progesterone receptor; ORR; overall response rate; RT-PCR; ERBB2; PFS; RT-qPCR; tamoxifen; estrogen receptor α; epidermal growth factor receptor 2; expression; OR; CI; progression-free survival; reverse transcriptase PCR; ER; mutation; MAF; minor allele frequency; hazard ratio; confidence interval; Tamoxifen; Recurrent breast cancer; Expression; Mutation
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2016.03.038

Highlights • GATA3 mutations were identified among 14% of ER-positive breast cancer patients • GATA3 mutations did not predict the response to tamoxifen for advanced disease • GATA3 mutations associate with an increased expression of GATA3 mRNA • GATA3 mRNA level is an independent predictor of longer PFS during tamoxifen therapy • Other mechanisms, besides GATA3 mutations, exist that underlie high GATA3 levels